Overview

Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development

Status:
Recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

The aim of this study is to assess the efficacy of oral administration of simvastatin plus rifaximin in patients with decompensated cirrhosis to halt the progression of the disease as assessed by prevention of the development of ACLF

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Judit Pich

Treatments:

Rifamycins
Rifaximin
Simvastatin